By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on Oncology have been presented. According to news originating from Bratislava, Slovakia, by NewsRx correspondents, research stated, "Mesenchymal stromal cells (MSCs) represent heterogeneous cell population suitable for cell therapies in regenerative medicine. MSCs can also substantially affect tumor biology due to their ability to be recruited to the tumor stroma and interact with malignant cells via direct contacts and paracrine signaling."
Our news journalists obtained a quote from the research from Comenius University, "The aim of our study was to characterize molecular changes dictated by adipose tissue-derived mesenchymal stromal cells (AT-MSCs) and the effects on drug responses in human breast cancer cells SKBR3. The tumor cells were either directly cocultured with AT-MSCs or exposed to MSCs-conditioned medium (MSC-CM). Changes in cell biology were evaluated by kinetic live cell imaging, fluorescent microscopy, scratch wound assay, expression analysis, cytokine secretion profiling, ATP-based viability and apoptosis assays. The efficiency of cytotoxic treatment in the presence of AT-MSCs or MSCs-CM was analyzed. The AT-MSCs altered tumor cell morphology, induced epithelial-to-mesenchymal transition, increased mammosphere formation, cell confluence and migration of SKBR3. These features were attributed to molecular changes induced by MSCs-secreted cytokines and chemokines in breast cancer cells. AT-MSCs significantly inhibited the proliferation of SKBR3 cells in direct cocultures which was shown to be dependent on the SDF-1a/CXCR4 signaling axis. MSC-CM-exposed SKBR3 or SKBR3 in direct coculture with AT-MSCs exhibited increased chemosensitivity and induction of apoptosis in response to doxorubicin and 5-fluorouracil."
According to the news editors, the research concluded: "Our work further highlights the multi-level nature of tumor-stromal cell interplay and demonstrates the capability of AT-MSCs and MSC-secreted factors to alter the anti-tumor drug responses."
For more information on this research see: Altered features and increased chemosensitivity of human breast cancer cells mediated by adipose tissue-derived mesenchymal stromal cells. BMC Cancer, 2013;13():38-50. BMC Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Cancer - www.biomedcentral.com/bmccancer/)
The news correspondents report that additional information may be obtained from L. Kucerova, Comenius Univ, Fac Med, Inst Histol & Embryol, Bratislava, Slovakia. Additional authors for this research include S. Skolekova, M. Matuskova, M. Bohac and Z. Kozovska (see also Oncology).
Keywords for this news article include: Biomedical Engineering, Biomedicine, Europe, Slovakia, Oncology, Bratislava, Breast Cancer, Stromal Cells, Bioengineering, Women's Health, Regenerative Medicine, Connective Tissue Cells
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC